BioLineRx Shares Fall After Announcing $3.75 Million Discounted Stock Offering

Shares of BioLineRx Ltd. (NASDAQ: BLRX) fell in premarket trading Friday after the biopharmaceutical company announced plans for a registered direct offering of its American Depositary Shares (ADSs) priced below the stock's recent market value.

Offering Details

BioLineRx has entered into a definitive agreement to sell 1,348,921 ADSs at a price of $2.78 per share, according to a company statement. The offering is expected to generate gross proceeds of approximately $3.75 million before deducting placement agent fees and other expenses.

The company stated it intends to use the net proceeds for research and development activities, as well as for working capital and general corporate purposes. The offering, for which Chardan is the exclusive placement agent, is expected to close on or about August 31, 2026.

Market Impact and Terms

Ad

In response to the announcement, BioLineRx shares dropped 4.4% in premarket trading. Capital raises priced below the current market price are typically dilutive to existing shareholders because they increase the total number of shares outstanding, often causing a near-term decline in the stock price.

The offering also includes warrants to purchase up to an additional 2,023,382 ADSs at an exercise price of $2.78, expiring five years from issuance. Concurrently, BioLineRx amended existing warrants with the investor, reducing the exercise price to $2.78 and extending the expiration date to 2031, effective upon the closing of the new offering.

Company Background

BioLineRx is a clinical-stage company focused on developing therapies for oncology and rare diseases. The company's first approved product, APHEXDA (motixafortide), is indicated in the U.S. for stem cell mobilization in multiple myeloma patients.